Lifestyle trends and health tips
Bristol Myers Squibb receives FDA clearance for a novel myeloma treatment, while PBMs shift towards greater price transparency with TrumpRx comparisons.
Bristol Myers Squibb's approval of Zenbexus for multiple myeloma highlights its new drug class, while a lawsuit over delayed approvals remains unresolved.
Bristol Myers Squibb's Zenbexus, a groundbreaking oral therapy for multiple myeloma, has gained FDA approval, marking a significant milestone in treatment options.
The CMS's recent ruling against funding pediatric gender-affirming treatment could face robust legal challenges, impacting future healthcare practices.
Community connections are vital for health yet overlooked in the U.S. and U.K. healthcare funding and discussions.
Commure has suspended payments under its referral program tied to AI products, just days before a critical investigation was published.
Splitting the MMR vaccine could lead to missed doses and increased illness among children, echoing past lessons from vaccine history.
FDA nixes a radiopharma drug by ITM Isotope Technologies, while Hims & Hers plans to enter the peptides market amidst evolving regulations.
Skylark Bio has initiated a clinical trial aimed at treating hearing loss in children with GJB2 mutations, following advancements in gene therapy.
Abortion care is evolving, with patients increasingly turning to digital solutions for reliable information and medical guidance.
Nurses are increasingly spotlighting the risks of clinical AI, advocating for a collaborative approach to its development and deployment in healthcare.
The FDA has rejected ITM-11 due to manufacturing concerns, hindering its potential as a competitor to Novartis’ treatment for rare neuroendocrine tumors.
The FDA now requires manufacturers to disclose food additive details, enhancing oversight for substances previously lacking regulation.
The recent Senate hearings on Covid-19's origins spotlight political distractions, while China's suppression of information remains a pivotal issue.
The NIH's proposed changes to funding eligibility may limit opportunities for international researchers on visas in the U.S. biomedical sector.
Replimune's new melanoma treatment gains FDA approval, while a Medicare policy change delays price negotiations for AbbVie drugs.
Replimune's advanced melanoma drug, RP1, receives FDA approval after a challenging path, bringing hope to patients with a hefty price tag.
A recent Medicare policy change has postponed the price negotiations for a major AbbVie drug, potentially impacting taxpayers significantly.
The FDA has approved Takeda's Orzeyful, a new orexin receptor agonist that promises to improve daytime alertness for narcolepsy patients.
Federal health officials convene with major tech firms to discuss the future of clinical AI, aiming for safe implementation and regulatory clarity.